Mebufotenin

Mebufotenin

SCHEMBL29993265

[2H]C([2H])([2H])N(CCc1c[nH]c2ccc(OC)cc12)C([2H])([2H])[2H]

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.82
HTR1A P08908 5/20 0.82
HTR6 P50406 5/20 0.82
HTR1D P28221 5/20 0.82
HTR1B P28222 4/20 0.82
HTR2C P28335 3/20 0.82
HTR7 P34969 3/20 0.82
HTR2B P41595 3/20 0.82
CYP1A2 P05177 2/20 0.82
CYP2D6 P10635 2/20 0.82
HTR4 Q13639 2/20 0.82
HTR1E P28566 2/20 0.82
HTR5A P47898 2/20 0.82
MTNR1A P48039 2/20 0.82
HTR3E A5X5Y0 1/20 0.82
HTR3B O95264 1/20 0.82
CYP2C9 P11712 1/20 0.82
HTR1F P30939 1/20 0.82
HTR3A P46098 1/20 0.82
MTNR1B P49286 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mebufotenin SCHEMBL30959017 1.00 HTR2A (0.82) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL29351950 0.90 HTR1D (1.00) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL27221706 0.90 HTR1D (1.00) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL132733 0.90 HTR1D (1.00) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL31098269 0.90 HTR1D (1.00) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL25330504 0.89 HTR1D (0.97) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL26111484 0.89 HTR1D (0.97) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL30601940 0.88 HTR2A (0.64) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL30601939 0.88 HTR2A (0.67) HTR2AHTR1AHTR6HTR1DHTR1B
Mebufotenin SCHEMBL25184829 0.88 HTR2A (0.67) HTR2AHTR1AHTR6HTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4398871-A1 COMBINATION DRUG THERAPIES Cybin IRL Limited (IE) 2024-07-17 EP claimed
WO-2023036473-A1 COMBINATION DRUG THERAPIES CYBIN IRL LIMITED (IE) 2023-03-16 WO claimed
EP-4704806-A1 INJECTABLE PHARMACEUTICAL FORMULATIONS Cybin IRL Limited (IE) 2026-03-11 EP disclosed
WO-2024231331-A1 INJECTABLE PHARMACEUTICAL FORMULATIONS CYBIN IRL LIMITED (IE) 2024-11-14 WO disclosed
EP-4398871-A1 COMBINATION DRUG THERAPIES Cybin IRL Limited (IE) 2024-07-17 EP disclosed
EP-4334285-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS Kare Chemical Technologies Inc. (CA) 2024-03-13 EP disclosed
WO-2023036473-A1 COMBINATION DRUG THERAPIES CYBIN IRL LIMITED (IE) 2023-03-16 WO disclosed
WO-2022232931-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS KARE CHEMICAL TECHNOLOGIES INC. (CA) 2022-11-10 WO disclosed